A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma

• DOI: 10.1126/scitranslmed.3002004
• Publication Date: 2011-06-01T18:30:47Z
• Authors: Natsuko Suwaki; Elsa Vanhecke; Katelyn M. Atkins; Manuela Graf; Katherine Swabey; Paul Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B. Kaye; James Larkin; Martin. E. Gore; Charles L. Sawyers; Peter Nelson; Tomasz M. Beer; Hao Geng; Lina Gao; David Z. Qian; Joshi J. Alumkal; Gary Thomas; George V. Thomas
• Keywords: Protein Tyrosine Phosphatase, Non-Receptor Type 1; 0301 basic medicine; Dasatinib; 610; 610 Medicine & health; 2700 General Medicine; In Vitro Techniques; Immunohistochemistry; 3. Good health; Thiazoles; 03 medical and health sciences; Pyrimidines; src-Family Kinases; Drug Resistance, Neoplasm; Von Hippel-Lindau Tumor Suppressor Protein; 10049 Institute of Pathology and Molecular Pathology; Cell Line, Tumor; Humans; Immunoprecipitation; Carcinoma, Renal Cell; Protein Kinase Inhibitors; Cell Proliferation; Signal Transduction

Signaling through the VHL-PTP1B-Src pathway in renal cell carcinomas may determine sensitivity to Src inhibitors and provide a basis for treatment planning.